Veracyte (VCYT) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
- Intel shares drop on foundry risks, sector pressures
Veracyte Announces Third Quarter 2015 Financial Results
November 5, 2015 4:05 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent business progress. Revenue for the third quarter of 2015 was $12.3 million, an increase of 25%, compared to $9.8 million for the third quarter of 2014. Afirma Gene Expression Classifier (GEC) test volume grew to 5,034 tests, an increase of 46%, compared to the same period in 2014.
"We experienced robust growth in our Afirma business, driven in... More



